http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
형질전환 비만모델 수컷 hGHTg rats에서 경신해지환(輕身解脂丸)이 혈중 항비만지표에 미치는 영향
정양삼,총배금,최승배,김경철,신순식,Jung, Yang-Sam,Tsung, Pei-Chin,Choi, Seung-Bae,Kim, Gyeong -Cheol,Shin, Soon-Shik 대한한의학방제학회 2005 大韓韓醫學方劑學會誌 Vol.13 No.2
Objectives: To find out the effects GGTl, an antiobestic drug widely used in clinics, has on the blood-antiobestic index and the toxicity index using the data from the hGHTg obese male rats. We looked closely into both of the two indices because GGTl antiobestic effect can happen not only by pharmacological action, but also by its toxicity. Also, we verified the difference in effect between GGTl and reductil (sibutramine), which has been approved by the FDA of the United States. Methods: After performing the experiments for 8 weeks on the hGHTg obese male rats divided into three groups: the control group, the GGTl group, and the reductil (RD) group, we anesthetized the rats with Diethyl ether and took a 3ml blood sample from the heart. Then, after coagulating the blood in room temperature by using the plasma separator, we centrifuged it for 25 minutes in 3,000rpm using the high-speed refrigerated centrifuge. We kept the separated plasma in a deep freezer at $-80^{\circ}C$, and repeatedly measured the antiobestic index and the toxicity index twice using the hematology biochemistry analyzer. Also, in order to judge the indirect toxicity index, we separated liver from kidney and observed them. Results: When we looked at the results of the analysis of covariance on the measuring elements related to the antiobestic index (TC, HDL, LDL, TG, and GLU), there was no significant difference among the groups in all measuring elements. Also, the results of the analysis of covariance on the two roups (RD group and GGTl group) showed that the p-values had no significant difference under the level of significance 0.05. When we looked at the result of the analysis of covariance on the measuring elements related to the toxicity index (GOT, GPT, GGT, CREA, UA, ALB, and TP), we could see that the p-values in GPT, ALB, and TP have a significant difference among the groups. Also, the results of the analysis of covariance about the measuring elements related to the toxicity index on both groups, RD group and GGTl group, showed no significant difference in the p-values of all of the measuring elements in the two groups, RD and GGTl group. Conclusions: In conclusion, through this experiment, the safety of GGTl has been approved, and although the verification on its medical effect has not been clearly approved, when we consider the fact that it belongs to the same group as reductil, an antiobestic drug approved by the FDA of the United States, we could indirectly verify that GGTl has an antiobestic effect. We believe that when doing a sample design for a future experiment, it needs to be performed on a greater sample size based on the power analysis that needs to be performed primarily in experiments, and a more accurate verification is needed through more systematic experiment plans.
형질전환 비만모델 hGHTg 쥐를 이용한 경신해지환이 비만에 미치는 영향 - 혈중 항비만지표와 독성지표를 이용하여 -
정양삼,윤기현,최승배,강창완,신순식 한국자료분석학회 2005 Journal of the Korean Data Analysis Society Vol.7 No.4
In the present society, overeating led to a serious trouble for corpulence according to wealthy. Obesity speaks state that when energy intake is more than energy wastage. treatment drugs that present the United States of America FDA approves special skill use are it by 2 sorts only(sibutramine(reductil) and orlistat(xenical)). But, because is not used widely by some limiting point(LP)s both this two medicine, efficiency is high port charge, and side effect development of drugs with new action mechanism of the enemy urgently require. Therefore, in this study, we develop renewal cancellation file(GGT1) that is herb medicine that can supplement shortcoming of efficacious medicine. And we consider about synonymy and safety about different view corpulence depression effect using the hGHTg(human growth hormone transgeneic) obese rats. 현대사회에 들어서 생활이 윤택해짐에 따라 과도한 에너지를 섭취함으로써 비만에 대한 심각한 문제를 야기하고 있다. 현재 미국 FDA에서 인정하고 있는 비만치료제는 sibutramine(reductil)과 orlistat(xenical) 두 가지 뿐으로 비만의 해결 방안으로 비만에 대한 신약개발은 중요한 과제라고 할 수 있다. 그러나, 이 두 가지 약제 모두 몇 가지 제한점으로 인해 널리 사용되지 못하고 있기 때문에 신약개발은 더욱 더 많은 연구가 필요한 분야이다. 따라서 본 연구에서는 한방 비만제로서 경신해지환을 개발하여 형질전환 비만모델 hGHTg 쥐를 실험동물로 하여 얻어진 자료를 토대로 비만치료제로서 효과가 있는지 알아보고, 약제의 안전성에 대해서 알아본다.
경신해지환이 혈중 항비만지표와 독성지표에 미치는 효과에 관한 연구 - 고지방식이 수컷 비만 쥐를 대상으로 -
정양삼,윤기현,최승배,강창완,신순식 한국자료분석학회 2005 Journal of the Korean Data Analysis Society Vol.7 No.3
Corpulence speaks state that when energy intake is more than energy wastage, internal deposit fat is accumulated excessively and ruins health. Also, corpulence is threatening human's health as well as problem of beauty art. Corpulence treatment drugs that present the United States of America FDA approves special skill use are it by 2 sorts only(sibutramine(reductil) and orlistat(xenical)). But, because is not used widely by some limiting point(LP)s both this two medicine, efficiency is high port charge, and side effect development of drugs with new action mechanism of the enemy urgently require. Therefore, in this study, we develop renewal cancellation file(GGT1) that is herb medicine that can supplement shortcoming of efficacious medicine. And we consider about synonymy and safety about different view corpulence depression effect. 비만은 에너지 섭취량이 에너지 소모량보다 많을 때 체내지방이 과도하게 축적되어 건강을 해치는 상태를 말한다. 비만이 미용상의 문제뿐만 아니라 인간의 건강을 위협하고 있고, 더 나아가 사망률과 이환률을 증가시키는 만성질환이라고 할 수 있다. 현재 미국 FDA가 장기사용을 승인한 비만치료약물은 2가지 뿐으로 sibutramine(reductil)과 orlistat(xenical)이 그것이다. 그러나, 이 두 가지 약제 모두 몇 가지 제한점으로 인해 널리 사용되지 못하고 있기 때문에 항비만 효과는 높고, 부작용이 적은 새로운 작용기전을 가진 약물의 개발이 절실히 요구되고 있다. 따라서 본 연구에서는 양약제제의 단점을 보완하고 종합적으로 접근 가능한 한약제제인 항비만 한약제제인 경신해지환(GGT1)을 개발하여, 이의 비만 억제효과에 대한 유의성과 안전성에 대해서 알아본다.
신체부위별 측정변인에 따른 경신강지환16의 비만 개선효과 평가
정양삼,윤기현,최승배,윤미정,신순식,Jung, Yang-Sam,Yoon, Ki-Hyeon,Choi, Seung-Bae,Yoon, Mi-Chung,Shin, Soon-Shik 대한한의학방제학회 2008 大韓韓醫學方劑學會誌 Vol.16 No.1
In this study, we measured body mass index, visceral fat ratio and 6 parts of body, neck circumference, circumference of upper arm, chest circumference, abdomen circumference, hip circumference, and thigh circumference by bioimpedence analysis system, after taking Gyeongshingangjeehwan16 (GGEx16) in five months except the first period before taking GGEx16 on 49 women who are obesity or high-level obesity. In order to examine the significance test for the effect of obesity improvement of GGEx16, we practices repeated measure ANOVA with values of measurement variables in 6 monthly times. As a result of all measurement variables, there were significant difference (P-value=0.001). Therefore, we can say that GGEx16 is effective about obesity improvement. As it dramatically decreased between second measure period and first measure period for all measure variables, we can see that there were the most effect of GGEx16 in the first time after taking GGEx16. It is known that a important measurement variable to have a effect for obesity improvement about two variable which are body mass index and visceral fat ratio is waist circumference through correlation analysis. The result of whether there are differences to effect of obesity improvement for GGEx16 around the climacteric, there were significant difference for the effect of obesity improvement for GGEx16 around the climacteric about all parts of body (P-value=0.001). There were also powerfully difference in effect of obesity improvement for GGEx16 around the climacteric about all parts of body (P-value=0.001). Especially, the climacteric before is more effective than the climacteric after in the aspect of the effect of GGEx16.
고지방식이 비만마우스 모델에서 파키스탄산 및 중국산 마황으로 조성된 강지환(降脂丸)-1,2,3,4과 降脂丸-1+가미소체환(加味消滯丸)의 비알콜성 지방간질환 개선효과 비교
정양삼 ( Yang Sam Jung ),김종훈 ( Jong Hoon Kim ),김병출 ( Byeong Chul Kim ),석화준 ( Hoa Jun Seok ),유재상 ( Jae Sang Yoo ),구자룡 ( Ja Ryong Ku ),윤기현 ( Ki Hyeon Yoon ),조주흠 ( Ju Heum Jo ),장두현 ( Du Hyon Jang ),윤호영 ( Ho 대한본초학회 2014 大韓本草學會誌 Vol.29 No.6
Objectives : This study investigated the improvement effects of Gangjihwan-1,2,3,4 (DF-1,2,3,4) and combination of DF-1 and Gamisochehwan (GSH) on nonalcoholic fatty liver disease in a high fat diet-fed obese mouse model. Methods : Eight-week-old C57BL/6N mice were divided into eight groups: a normal lean group given a standard diet, an obese control group given a high fat diet, and atorvastatin, DF-1,2,3,4, and DF-1+GSH groups given a high fat diet with atorvastatin (10 mg/kg), DF-1,2,3,4 (40, 80, 160, 80 mg/kg), and DF-1+GSH (80 mg/kg), respectively. After 8 weeks of treatment, body weight gain, blood lipid markers, ALT concentrations, liver weight and histology were examined. Results : Body weight gain was significantly decreased in DF-1,2,3,,4, DF-1+GSH and atorvastatin groups compared with control. The extent of decreases was eminent in DF-1+GSH group. Circulating concentrations of total cholesterol and LDL-cholesterol were significantly decreased in DF-2, DF-4, DF-1+GSH and atorvastatin groups compared with control. Liver weights, hepatic lipid accumulation and hepatic fibrosis were significantly decreased in DF-1,2,3,4, DF-1+GSH and atorvastatin groups compared with control, and the magnitude of which was more effective in DF-1+GSH group than in DF-only group. Circulating ALT concentrations were significantly decreased only in DF-4 and DF-1+GSH groups. Conclusions : In conclusion, these results suggest that DF decreases body weight gain, improves blood lipid metabolism, and reduces liver weight and hepatic lipid accumulation and hepatic fibrosis, contributing to the improvement of nonalcoholic fatty liver disease. In addition, these effects were more effective in DF-1+GSH combination group than in DF-only group.